| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2972156 | The Journal of Heart and Lung Transplantation | 2009 | 7 Pages |
Abstract
The use of long-term anti-CD25 MAb therapy as a potential replacement for CNI- and rapamycin-based immunosuppression is feasible. It is crucial that rejection surveillance be intensified. A randomized, controlled trial is required to confirm the benefits and safety of this strategy.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Marcelo MD, Nadia MD, Jean-Pierre MD, Renzo MD, Jeffrey MD,